UPCC 02521 A Randomized Phase II Trial of Cabozantinib Combined with PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Enrolling By Invitation
99 years or below
All
Phase
2
1 Location
Brief description of study
This research study is designed to learn more about how soft tissue sarcomas respond to treatment with different sequences of a combination of three drugs: cabozantinib, nivolumab, and ipilimumab when given to individuals who have been diagnosed with Metastatic Soft Tissue Sarcoma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: sarcoma
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 848626
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
